echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Biositu and BeiGene Reach a Collaboration on the Licensed Use of RenMab/RenLite Fully Human Antibody in Mice

    Biositu and BeiGene Reach a Collaboration on the Licensed Use of RenMab/RenLite Fully Human Antibody in Mice

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, March 10, 2022 /PRNewswire/ -- Biositu (Beijing) Pharmaceutical Technology Co.


    The fully human antibody mouse RenMice platform (RenMab® and RenLite®) was developed by Biositu over a period of 5 years using the self-developed super-segment chromosome engineering technology SUPCE


    BeiGene is a global, science-based biotechnology company committed to being a game-changer in the global biopharmaceutical industry, focused on developing innovative, affordable medicines that improve outcomes and accessibility for patients around the world


    Regarding this cooperation, Dr.


    Dr.


    Source: Biositu

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.